ReviewFrontiers in pediatrics2021
T Lymphocytes, Multi-Omic Interactions and Bronchopulmonary Dysplasia.
Review in Frontiers in pediatrics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- Efficacy of pharmacologic therapies for reducing bronchopulmonary dysplasia and mortality in preterm infants: a network meta-analysis.BMC pediatrics · 2026Pooled it
- Development of a peripheral blood transcriptomic gene signature to predict bronchopulmonary dysplasia.American journal of physiology. Lung cellular and molecular physiology · 2023Trial
- Bacillus coagulans BC66 Attenuates Klebsiella pneumoniae-Induced Acute Lung Injury in Rabbits Associated With Modulation of Th17/Treg Immune Balance and Through the Keap1/Nrf2/HO-1 Signalling Pathway.Probiotics and antimicrobial proteins · 2026Article
- A Pilot Multi-Omics Approach Unveils Strong Immune Activation in the First Ten Days of Life in Extremely Preterm Infants.Metabolites · 2025Article
- Article
- Advancements in biomarkers and machine learning for predicting of bronchopulmonary dysplasia and neonatal respiratory distress syndrome in preterm infants.Frontiers in pediatrics · 2025Review
- Analysis and validation of necroptosis-related diagnostic biomarkers associated with immune infiltration in bronchopulmonary dysplasia.Frontiers in pediatrics · 2025Article
- Implication of m6A Methylation Regulators in the Immune Microenvironment of Bronchopulmonary Dysplasia.Biochemical genetics · 2024Article
- Leveraging transcriptomics to develop bronchopulmonary dysplasia endotypes: a concept paper.Respiratory research · 2023Article
- Multiomic Investigations into Lung Health and Disease.Microorganisms · 2023Review
- The Proportion of Recent Thymic Emigrant Lymphocytes in Breastfed and Formula Fed Term Neonates.Nutrients · 2023Article
- CD8A is a Promising Biomarker Associated with Immunocytes Infiltration in Hyperoxia-Induced Bronchopulmonary Dysplasia.Journal of inflammation research · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bronchopulmonary dysplasia (BPD) remains a significant clinical challenge in neonatal medicine. BPD is clearly a multifactorial disease with numerous antenatal and postnatal components influencing lung development. Extremely immature infants are born in the late canalicular or early saccular stage and usually receive intensive care until the early alveolar stage of lung development, resulting in varying magnitudes of impairment of alveolar septation, lung fibrosis, and abnormal vascular development. The interactions between T lymphocytes, the genome and the epigenome, the microbiome and the metabolome, as well as nutrition and therapeutic interventions such as the exposure to oxygen, volutrauma, antibiotics, corticosteroids, caffeine and omeprazole, play an important role in pathogenesis and disease progression. While our general understanding of these interactions thanks to basic research is improving, this knowledge is yet to be translated into comprehensive prevention and clinical management strategies for the benefit of preterm infants developing BPD and later during infancy and childhood suffering from the disease itself and its sequelae. In this review, we summarise existing evidence on the interplay between T lymphocytes, lung multi-omics and currently used therapeutic interventions in BPD, and highlight avenues for potential future immunology related research in the field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.